523 related articles for article (PubMed ID: 30686591)
1. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
2. Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.
Álvarez-Quilón A; Wojtaszek JL; Mathieu MC; Patel T; Appel CD; Hustedt N; Rossi SE; Wallace BD; Setiaputra D; Adam S; Ohashi Y; Melo H; Cho T; Gervais C; Muñoz IM; Grazzini E; Young JTF; Rouse J; Zinda M; Williams RS; Durocher D
Mol Cell; 2020 Jun; 78(6):1152-1165.e8. PubMed ID: 32516598
[TBL] [Abstract][Full Text] [Related]
3. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
5. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
De Summa S; Pinto R; Pilato B; Sambiasi D; Porcelli L; Guida G; Mattioli E; Paradiso A; Merla G; Micale L; De Nittis P; Tommasi S
Cell Death Dis; 2014 Feb; 5(2):e1076. PubMed ID: 24556691
[TBL] [Abstract][Full Text] [Related]
6. PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.
Andronikou C; Burdova K; Dibitetto D; Lieftink C; Malzer E; Kuiken HJ; Gogola E; Ray Chaudhuri A; Beijersbergen RL; Hanzlikova H; Jonkers J; Rottenberg S
EMBO J; 2024 Mar; 43(6):1015-1042. PubMed ID: 38360994
[TBL] [Abstract][Full Text] [Related]
7. A role for human homologous recombination factors in suppressing microhomology-mediated end joining.
Ahrabi S; Sarkar S; Pfister SX; Pirovano G; Higgins GS; Porter AC; Humphrey TC
Nucleic Acids Res; 2016 Jul; 44(12):5743-57. PubMed ID: 27131361
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.
Ward TA; McHugh PJ; Durant ST
PLoS One; 2017; 12(6):e0179278. PubMed ID: 28628639
[TBL] [Abstract][Full Text] [Related]
9. Proliferating cell nuclear antigen prevents trinucleotide repeat expansions by promoting repeat deletion and hairpin removal.
Beaver JM; Lai Y; Rolle SJ; Liu Y
DNA Repair (Amst); 2016 Dec; 48():17-29. PubMed ID: 27793507
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
11. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
[TBL] [Abstract][Full Text] [Related]
12. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.
Sultana R; McNeill DR; Abbotts R; Mohammed MZ; Zdzienicka MZ; Qutob H; Seedhouse C; Laughton CA; Fischer PM; Patel PM; Wilson DM; Madhusudan S
Int J Cancer; 2012 Nov; 131(10):2433-44. PubMed ID: 22377908
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
16. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Patel PS; Algouneh A; Hakem R
Oncogene; 2021 Apr; 40(17):3001-3014. PubMed ID: 33716297
[TBL] [Abstract][Full Text] [Related]
17. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
Murai J; Pommier Y
Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Abdel-Fatah TM; Perry C; Arora A; Thompson N; Doherty R; Moseley PM; Green AR; Chan SY; Ellis IO; Madhusudan S
Antioxid Redox Signal; 2014 Dec; 21(16):2262-8. PubMed ID: 25111287
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
